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Abstract 
Gram-positive streptococci are non-motile, chain-forming bacteria commonly found in 
the normal oral and bowel flora of warm-blooded animals. Over the past decade, a 
proteomic approach combining 2-DE and MS has been used to systematically map the 
cellular, surface-associated and secreted proteins of human pathogenic streptococcal 
species. The public availability of complete streptococcal genomic sequences and the 
amalgamation of proteomic, genomic and bioinformatic technologies have recently 
facilitated the identification of novel streptococcal vaccine candidate antigens and 
therapeutic agents. The objective of this review is to examine the constituents of the 
streptococcal cell wall and secreted proteome, the mechanisms of transport of surface 
and secreted proteins, and describe the current methodologies employed for the 
identification of novel surface-displayed proteins and potential vaccine antigens.  
 3
1 Introduction – Streptococcal infection of humans 
The Genus Streptococcus consists of numerous Gram-positive, non-motile, chain-
forming cocci commonly found in the normal oral and bowel flora of warm-blooded 
animals. Streptococci are a diverse group of bacteria capable of colonizing and infecting 
a broad spectrum of host organisms and tissues. The Genus is comprised of 49 species 
and 8 subspecies of which 35 have been isolated as a source of infection in humans [1]. 
Pathogenic streptococcal species fall into three broad categories: pathogenic species 
commonly causing infection in humans; commensal species and zoonotic species which 
under the right conditions cause opportunistic infection in humans. Streptococcus 
pyogenes (group A Streptococcus; GAS), S. agalactiae (group B Streptococcus; GBS), S. 
pneumoniae, and S. mutans are pathogenic streptococcal species commonly causing 
infection in humans (Table 1). GAS colonizes the mucosa of the respiratory tract and skin 
causing, most commonly, pharyngitis and pyoderma. When S. pyogenes colonizes 
normally sterile tissues severe invasive disease may result [2, 3]. GBS is a commensal 
bacterium colonizing the intestinal tract of a significant proportion of the human 
population; it is also a pathogen that invades a number of different host compartments 
and may cause severe neonatal infections [4-7]. S. pneumoniae is a commensal 
streptococcal species carried asymptomatically in up to 60% of the population. The 
pneumococcus is also responsible for a significant burden of disease in children under the 
age of 2 years, the elderly and patients with immunodeficiencies causing diseases 
including pneumonia, meningitis, and otitis media [8, 9]. S. mutans is the main causative 
agent of human dental caries, one of the most common infectious diseases afflicting 
humans [10]. Infection by commensal and zoonotic streptococcal species occur primarily 
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in immunocompromised individuals and the elderly [11-15]. Commensal organisms 
colonizing the oral mucosa, the surface of teeth (organisms of the groups S. mitis, S. 
mutans, S. salivarius, S. anginosus) and other mucosal niches (S. anginosus group), may 
cause infective endocarditis and have also been associated with serious suppurative 
infections (Table 1) [10, 16-19]. A few species of Streptococcus with reservoirs in 
animals have proven to be zoonotic, including species from horses (S. dysgalactiae subsp. 
equisimilis, S. equi subsp. zooepidemicus), cattle (members of the S. bovis group), dogs 
(S. canis), pigs (S. porcinus, S. suis), fish (S. iniae), and chickens (S. gallinaceus). 
Zoonotic species most commonly cause invasive disease and have been associated with 
toxin-mediated infections [12, 14, 20-24] (Table 1). Zoonotic streptococcal species are 
primarily food borne or transmitted through cuts and abrasions [12]. Table 1 highlights 
the significant burden of disease caused by human pathogenic streptococcal species. 
The complete genome has been sequenced for multiple strains of S. pyogenes 
[25-30], S. agalactiae [31, 32], S. pneumoniae [33, 34] and S. suis [35] and a single 
strain of S. mutans [36]. The public availability of complete genome sequences 
coupled with adjunct technologies such as bioinformatics tools, proteomics, MS and 
N-terminal amino acid sequencing, has facilitated the compilation of comprehensive 
proteomic maps and the identification of promising target antigens for inclusion into 
vaccine formulations against human bacterial pathogens [37, 38].  This review will 
focus on the human pathogenic streptococci and cover 1) the secreted, surface and cell 
wall proteomes, 2) transport mechanisms for secreted, surface and cell wall proteins, 
and 3) advances in vaccine development and the role played by genomic and 
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proteomic data in informing the development of safe, efficacious, and broadly 
protective vaccines. 
2 Streptococcal proteomics 
Several different strategies are currently employed to identify bacterial surface proteins 
including: 1) an in silico genome-based strategy using algorithms such as PSORT to 
search complete genome sequences for putative proteins harboring cell wall anchor 
motifs and transmembrane domains; 2) the purification of surface-displayed proteins by 
chemical or enzymatic methods followed by 2-DE and identification by PMF; and 3) the 
cloning, expression and subsequent generation of antibodies against putative surface-
displayed proteins for whole-cell assays and/or electron microscopic analysis to confirm 
surface-localization [39]. In the majority of cases, surface-localized streptococcal proteins 
are isolated either by sequential chemical extraction, or enzymatic digestion of the 
peptidoglycan-containing cell wall with lysozyme or mutanolysin in an isosmotic buffer 
to minimize cell rupture and contamination of the preparation with cytoplasmic proteins 
[40]. The extracts are then fractionated by 2-DE, the excised protein spots digested with 
trypsin, and the peptide fragments analyzed by MALDI-TOF MS or MS/MS [40]. While 
this strategy has the capacity to identify anchorless cell surface proteins potentially 
overlooked with a computational genome-wide screening approach [41, 42], it typically 
detects a relatively small number of membrane-associated proteins [43, 44], due either to 
their inherent hydrophobicity and aggregation during IEF, or their low abundance within 
the cell wall [40]. To circumvent these problems, streptococcal surface proteins have 
recently been mapped using the techniques of reverse vaccinology, which involve: 1) the 
identification of numerous putative vaccine candidates by in silico analysis of complete 
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genome sequences; 2) the cloning, over-expression and purification of each recombinant 
antigen; and 3) the subsequent active immunization of mice to test for immunological 
protection [45]. This strategy has been successfully used for identification of novel 
antigens in S. pyogenes [46-49] and S. agalactiae [50]. 
Two-dimensional gel electrophoretic profiles, or reference maps, have been 
generated for numerous streptococcal spp. [38, 51-56]. Basic reference maps of soluble 
cytosolic proteins are routinely used to compare various strains of streptococci and 
identify changes in protein expression under physiological stresses [51, 57]. Pathogenic 
streptococci express a broad spectrum of multifunctional cell wall and surface-associated 
proteins which facilitate adherence to and invasion of host cells, evasion of the host 
immune response, and degradation of host proteins [2, 58]. Consequently, the surface 
proteins of these bacteria are often important targets for vaccine development. Several 
cell wall and surface-localized streptococcal antigens have been identified as promising 
vaccine candidates by immunoproteomic analyses [41, 43, 44, 59-62]. Many proteins are 
also secreted from the streptococcal cell surface into the extracellular milieu [38, 46, 56, 
62-65]. These proteins influence host-pathogen interactions and may contribute to 
disease. Gram-positive proteins destined for transport across the cytoplasmic membrane 
frequently contain a hydrophobic N-terminal signal sequence [66, 67]. Curiously, a 
number of secreted streptococcal proteins lack apparent secretion signal sequences [46, 
56, 66]; thus the mechanism by which these proteins are transported to the bacterial cell 
surface is yet to be elucidated. This section will describe the methodologies currently 
employed for the identification of streptococcal surface-displayed and secreted proteins, 
which represent potential vaccine antigens or therapeutic targets. 
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2.1 S. pyogenes cell wall and surface-associated proteome 
The initial proteomics-based identification of group A streptococcal cell wall and surface-
associated proteins was undertaken by Cole et al. [59]. Cell wall extracts were harvested 
by enzymatic digestion using a combination of lysozyme and mutanolysin. The muralytic 
enzyme mutanolysin cleaves the β-1,4 linkage of the N-acetylmuramyl-N-
acetylglucosamine in the glycan backbone of the highly conserved peptidoglycan-
polysaccharide polymer, and is routinely used for the preparation of streptococcal 
protoplasts [68, 69] and the solubilization of cell wall-associated proteins, with minimal 
leakage of cytoplasmic contents [70, 71]. Mutanolysin extracts harvested from in vitro 
stationary-phase cultures of three different S. pyogenes serotypes (M69, M53 and M6) 
were analyzed by 2-DE and the most abundant proteins identified by in-gel tryptic 
digestion and MALDI-TOF MS analysis. Interrogation of publicly available databases 
containing complete GAS genomic sequences identified a total of 74 distinct proteins, 66 
of which had not previously been characterized as cell wall-associated in GAS. In order 
to identify the immunoreactive cell wall-associated proteins, 2-D western blots of 
mutanolysin extracts were probed with pooled antisera from GAS-infected humans. This 
technique identified 33 immunoreactive cell wall proteins which are presumably 
expressed during the course of human infection. To determine which cell wall-associated 
proteins were surface-exposed, and hence potential vaccine candidate antigens, the GAS 
cell surface was biotinylated prior to mutanolysin extraction, 2-D immunoblotting and 
detection of biotin-labeled proteins with a streptavidin HRP conjugate. In the aggregate, 
23 cell wall-associated proteins were biotinylated and thus surface-exposed, illustrating 
the usefulness of high-throughput proteomics in elucidating novel vaccine candidate 
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antigens. Depending on the strain, S. pyogenes has 14-17 cell wall-associated proteins 
predicted from in silico analysis of completely sequenced genomes [39, 72, 73]. The 
study by Cole et al. [59] only identified 3/17 predicated cell wall-linked proteins. 
Furthermore, while this proteomic approach is quantitative, the enzymatic degradation of 
the bacterial cell wall may cause cell lysis and contamination of cell wall fractions with 
cytoplasmic proteins [40]. However, the use of mutanolysin, lysozyme and other 
biochemical methods for the extraction of surface-associated proteins followed by 2-DE, 
has a distinct advantage over in silico genome searches given that a significant number of 
such proteins lack N-terminal signal and C-terminal anchor sequences [43].  
Rodríguez-Ortega et al. [39] identified the surface-exposed proteins of S. 
pyogenes SF370 (serotype M1) by using a combination of biochemical, proteomic and 
bioinformatic techniques. Whole cells were treated in situ with proteolytic enzymes 
(trypsin or proteinase K individually, or in tandem) to “shave” the protruding cell surface-
associated proteins. The released peptide fragments were purified, analyzed by nano-
LC/MS/MS, and identified by searching the publicly available genome sequence of 
SF370 [39]. This approach identified 68 putative surface-associated proteins, including 
12 canonical cell wall proteins harboring the LPXTG cell wall-sorting motif, 11 
lipoprotein family proteins, 37 transmembrane proteins, and 8 secreted proteins. Only 4 
identified proteins were predicted cytosolic proteins, illustrating that digestion of 
bacterial surface proteins does not rupture the cells nor release contaminating cytoplasmic 
proteins [39]. PSORT topological prediction analysis and fluorescence-activated cell 
sorting with protein-specific antibodies raised in mice, confirmed the surface-localization 
of most identified proteins. Furthermore, the putative cell-envelope serine proteinase 
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Spy0416 identified in this study was protective against virulent DSM2071 GAS challenge 
in a mouse model of intranasal infection [39]. The methodology used in this study 
circumvents contamination issues associated with the preparation of cell wall proteins by 
conventional enzymatic methods, and provides a tool for the selective identification of 
bacterial surface-exposed proteins and new vaccine candidates. This approach is also 
cheaper and less labor-intensive than the in silico genome-based strategy employed by 
Maione et al. [50], which involved the cloning, over-expression, and purification of 312 
surface proteins of S. agalactiae, only 4 of which were protective in a mouse infection 
model [74]. However, Rodríguez-Ortega et al. [39] only identified 6.5% of PSORT-
predicted transmembrane proteins, suggesting that these proteins are either resistant to 
protease digestion, undergo complete proteolytic degradation, are poorly expressed, are 
differentially regulated, or are hidden within the bacterial cell membrane [39]. 
Furthermore, this investigation only utilized a single growth medium and harvested the 
bacteria at a single growth phase. It is well established that the proteome of S. pyogenes 
differs significantly according to growth conditions and the phase of growth, which may 
influence the composition of the S. pyogenes surfaceome [45]. Of note, the SF370 M1 
serotype differs significantly genetically from the globally disseminated M1T1 clone - the 
serotype responsible for a substantial proportion of severe invasive diseases, such as 
necrotizing fasciitis and streptococcal toxic shock syndrome [56, 75-77]. 
Severin and associates [40] also directly digested the surface-exposed proteins of 
S. pyogenes SF370 (serotype M1) with trypsin and identified the resultant peptide 
fragments by multidimensional nano-LC-MS/MS. However, in contrast to Rodríguez-
Ortega et al. [39], surface-associated proteins were harvested from cells grown to early- 
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and late-exponential phase to account for the well characterized growth phase-dependent 
differences in protein synthesis [52]. In silico genomic analysis was also employed to 
identify putative cell surface-associated proteins. This proteomic approach identified 79 
surface-associated proteins, including 33 proteins not previously characterized as being 
surface-localized in S. pyogenes. These proteins included 4/17 predicted cell wall anchor 
motif-containing proteins, 12/27 predicted lipoproteins, 9 secreted proteins, 22 
membrane-associated proteins, 1 bacteriophage-associated protein, and 21 proteins 
traditionally classified as cytoplasmic. In the aggregate, 58 of the 79 proteins identified in 
this study were predicted to be surface-localized by computer-assisted sequence analyses 
with well established algorithms. Cell surface-localization of some proteins (12 of 16 
tested) was confirmed by whole-cell ELISA using mouse antisera raised against purified 
recombinant protein. One of these, putative translation elongation factor Tu, is a 
traditional cytoplasmic protein involved in protein synthesis. Three hypothetical proteins 
exhibited high antibody titres [40], two of which are known to elicit protection against 
GAS challenge in a mouse model of infection [39, 48]. These findings suggest the 
method of direct digestion of bacterial surface-exposed proteins is an efficient way to 
identify putative surface antigens, which may facilitate the development of a safe and 
efficacious human vaccine. To avoid potential contamination of surface-exposed proteins 
with cytoplasmic proteins, whole cell tryptic digestion was performed in a buffer 
supplemented with D-arabinose, which promotes the formation of protoplasts in the event 
of cell wall hydrolysis. Cryo-field emission scanning electron microscopic analyses, 
viable cell counts, and the absence of the abundant cytoplasmic proteins lactate 
dehydrogenase and pyruvate oxidase, confirmed the integrity of whole-cells following 
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trypsin treatment [40]. Surprisingly, only 33 surface-exposed proteins were common to 
this study and the work of Rodríguez-Ortega et al. [39]. The differences in algorithms 
used for bioinformatic analyses, the stringency of matched peptides and protein 
identification, as well as differences in growth-phase, may account for this disparity [40].  
2.2 Secreted group A streptococcal proteome 
Several studies of the S. pyogenes proteome have focused on proteins released into the 
extracellular environment [46, 56, 64, 65]. Streptococcal pyrogenic exotoxin B (SpeB) is 
an extracellular and surface-associated cysteine protease virulence factor produced by 
most GAS strains [78]. Genetic inactivation of the speB gene or chemical inactivation of 
SpeB with the cysteine protease inhibitor E64, reveals that SpeB can efficiently degrade 
the majority of proteins in the secreted GAS proteome [46, 63, 79]. Using 2-DE and 
amino-terminal amino acid sequencing, Lei et al. [46] identified forty-four distinct 
proteins in the culture supernatants of two isogenic speB mutant GAS strains of serotypes 
M1 and M3, grown in vitro at 37°C. Many of these proteins had not previously been 
described in GAS and only sixteen of these had apparent secretion signal sequences, 
which included virulence factors streptolysin O, M protein, SpeA, SIC, and streptokinase. 
The remaining twenty-seven extracellular proteins identified had no apparent secretion 
signal sequences and included traditional cytosolic proteins such as glycolytic enzymes, 
chaperonins, protein translation factors, urea cycle proteins, ribosomal proteins, a DNA 
binding protein, and general housekeeping enzymes. Following 2-D western blot analyses 
with sera from GAS-infected mice and humans, many of the secreted proteins were found 
to be immunogenic and thus expressed during course of human infection [46]. The 
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absence of a signal peptide and LPXTG motif suggests that an alternative secretory 
pathway may exist for many secreted GAS proteins. 
2.3 S. pneumoniae cell wall and surface-associated proteome 
An immunoproteomics-based approach was used to identify novel S. pneumoniae vaccine 
candidates [44]. Enriched cell wall protein extracts from S. pneumoniae WU2 were 
resolved by 2-D electrophoresis and identified by MALDI-TOF MS. Two-dimensional 
western blot analysis using sera from children frequently exposed to S. pneumoniae and 
healthy adults, identified 17 common immunogenic proteins, 13 of which exhibited an 
age-dependent increase in antigenicity. Two of these proteins, identified as glycolytic 
enzymes fructose-bisphosphate aldolase (FBA) and glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), elicited cross-strain protective immunity against respiratory 
challenge with virulent pneumococci in a mouse model of intranasal infection [44]. 
However, this investigation only identified a relatively small number of streptococcal cell 
wall-associated proteins containing cell wall anchor motifs, despite bioinformatic 
predictions of 14-16 in S. pneumoniae [72, 80].  
Overweg and coworkers [61] isolated hydrophobic, surface-associated proteins 
from S. pneumoniae strain FT231 using the N-tetradecyl-N,N-dimethylammonio-1-
propanesulfonate (SB14) extraction procedure [81]. Following separation by 2-DE, 
individual proteins were identified by MS and N-terminal amino acid sequencing. Two of 
the three proteins identified as contributing to opsonophagocytic activity in vitro included 
the previously characterized pneumococcal surface protein A and the oligopeptide-
binding lipoprotein. The third protein was identified as the putative proteinase maturation 
protein A (PpmA). The surface localization of PpmA was confirmed using 
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immunoelectron microscopy, and the opsonophagocytic antibodies raised against PpmA 
were cross-reactive against several pneumococcal strains. In addition, PpmA was 
required for full virulence in a mouse pneumonia model. These data suggest that PpmA 
may be a suitable candidate antigen for inclusion in future pneumococcal vaccine 
formulations [61]. Additionally, proteomic analysis of mutanolysin cell wall extracts 
from S. pneumoniae WU2 (serotype 3) identified immunogenic proteins which may 
represent future targets for pneumococcal vaccine development [41]. These include 
traditional housekeeping proteins such as FBA, enolase, trigger factor, L-lactate 
dehydrogenase, pyruvate kinase, and phosphoglycerate kinase (PGK).  
 2.4 Group B streptococcal cell wall and surface-associated proteome 
A proteomic analysis was undertaken by Hughes et al. [43] to identify the most abundant 
surface-associated proteins of S. agalactiae. Mutanolysin extracts of outer cell surface 
proteins were separated by 2-DE and identified using MS and reverse genetic techniques. 
The absence of DNA in the protein extract confirmed the absence of intracellular 
contamination. In total, 27 major protein spots were identified, 6 of which were 
previously unidentified in S. agalactiae, including ornithine carbamoyltransferase (OCT), 
PGK, nonphosphorylating GAPDH, purine nucleoside phosphorylase, enolase, and 
glucose-6-phosphate isomerase. Two of the putative surface-displayed cytoplasmic 
enzymes, OCT and PGK, were cloned, over-expressed in vitro, and the purified 
recombinant proteins used to raise polyclonal antisera. The antibodies were used in 
subsequent whole-cell ELISAs to confirm the cell surface localization of each protein. 
Passive immunization with antibodies against OCT and PGK in a mouse model of 
neonatal intraperitoneal infection afforded some protection against lethal S. agalactiae 
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challenge (46 and 35% survival for anti-OCT and anti-PGK, respectively, versus 64 and 
2% survival for whole-cell positive control and preimmune serum, respectively), 
suggesting these proteins warrant further investigation as potential vaccine candidates 
[43]. Many of the anchorless surface-associated proteins identified by this proteomic 
approach may not have been identified by the conventional whole-genome screening 
strategy [82]. However, this method identified a relatively small number of streptococcal 
wall-associated proteins containing cell wall anchor motifs [43], despite genomic 
predictions of 25-35 proteins in S. agalactiae [72, 80]. Although labor intensive, this 
approach is quantitative and identifies bona fide surface-associated proteins [39]. 
2.5 S. mutans cell membrane-associated proteome 
Len et al. [38] generated proteomic reference maps for soluble cellular and extracellular 
proteins of S. mutans grown in continuous culture. However, this study only identified 
three proteins associated with the cellular membrane (WapA, Gbp and SpaP). Membrane-
associated proteins are frequently under-represented in proteomic reference maps due 
either to their low-abundance or hydrophobicity, which leads to poor solubility, 
aggregation during IEF, and poor resolution on 2-D gels [83-86]. Recently, Hasona et al. 
[87] undertook a systematic proteomic analysis of cytoplasmic membrane-associated 
proteins in S. mutans strain UA159 by combining 2-DE and nanoelectrospray quadruple 
time of flight (QTOF)-tandem MS/MS. Previously, only the cytoplasmic proteins of S. 
mutans had been characterized by 2-DE [88-92]. Zuobi-Hasona et al. [85] solubilized 
cellular membrane proteins from S. mutans UA159 using three different methods, arrayed 
the samples by 2-DE, and identified the proteins by QTOF MS/MS. Several known 
membrane- and surface-associated proteins were successfully identified, including 
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enolase, glucose 6-phosphate isomerase, PGK, GAPDH, and ribosomal protein L7/L12 
[85]. 
2.6 S. suis cell wall and surface-associated proteome 
Two temperature-induced surface-associated proteins of S. suis strain I9841/1 (serotype 
2) identified by a proteomic approach are highly homologous to members of the arginine 
deiminase system of S. pyogenes, including an OCT protein and the virulence factor 
streptococcal acid glycoprotein (SAGP) [93]. Immunoelectron microscopic analyses 
using anti-S. pyogenes SAGP antiserum confirmed the localization of the S. suis SAGP 
homologue, designated AdiS, on the streptococcal cell surface [93]. The surface 
localization, ubiquitous distribution of the adiS gene among S. suis strains, temperature-
induced expression, and high sequence homology with the SAGP virulence factor, 
suggest that AdiS may represent a temperature stress induced virulence factor in S. suis 
[93].  
In an attempt to identify the cell wall-associated proteins of S. suis harboring a C-
terminal LPXTG motif, guanidine-insoluble mutanolysin-released cell wall proteins from 
strain NCTC 10234 (serotype 2) deficient in srtA, a sortase-encoding gene, were analyzed 
by 2-DE. Comparison with the parent strain identified 15 missing proteins in the cell 
wall-linked protein file of the srtA mutant, which were restored upon complementation 
with cloned S. mutans srtA. Four of these proteins were identified by N-terminal amino 
acid sequence analysis and their putative genes were predicted to possess an N-terminal 
signal sequence and a C-terminal LPXTG motif. The proteomics-based strategy utilized 
in this study overcomes the lack of complete S. suis genome sequence data for in silico 
bioinformatic screening of novel cell wall-associated proteins [94].   
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3 Protein export 
Surface-exposed and secreted proteins are key players during the infectious process of 
streptococci and may serve as protective antigens for vaccine development. The first step 
in exporting proteins to the cell surface is the trafficking of protein across the cellular 
membrane. Several distinct pathways have been identified in Gram-positive bacteria for 
protein export from the cytoplasm via controlled translocation channels such as the 
general secretory (Sec) pathway, twin-arginine translocation (TAT) pathway, a pili-
specific secretion/assembly pathway, and the “ExPortal” system [95].  
3.1 Sec pathway 
The majority of Gram-positive bacterial proteins, including streptococcal proteins, are 
exported by the highly conserved Sec pathway (Figure 1). This pathway has been 
extensively characterised [95] and will not be further described in this review.     
3.2 TAT pathway 
The TAT pathway translocates folded proteins harbouring a distinctive twin-arginine 
motif in the signal peptide of the corresponding precursor proteins [95] and comprises the 
three functionally distinct membrane proteins, TatA, TatB, and TatC (Figure 1) [96]. 
While TatB and TatC are involved in the specific recognition of the substrate, TatA may 
be the major pore-forming component [96]. Homologs of TatA and TatC have been 
identified in S. thermophilus and these homologs appear to be absent in other streptococci 
[97].   
3.3 Pili-specific secretion/assembly pathway  
Pili in Gram-positive pathogens are formed by covalent polymerization of adhesive pilin 
subunits and are secreted through the cell membrane by the Sec machinery [67] (Figure 
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1). Sortase, as described below, is required for the polymerization of the pili subunits and 
attachment of pili to the bacterial cell surface. Pilin subunit proteins are synthesized as 
precursors carrying N-terminal signal peptide and C-terminal LPXTG motif [67]. The 
identification of pili in streptococcal species has only been recently published [98-100]. 
Pili of S. pyogenes serotype M1 promote adhesion to human tonsil epithelium and 
primary human keratinocytes and in the formation of biofilm [101, 102], while the pili 
proteins of S. agalactiae facilitate adherence and invasion of brain endothelium [103]. 
The pilus operons promoting synthesis and assembly of pili are found in genomic islands 
such as the FCT pathogenicity island in S. pyogenes [98], the rlrA pathogenicity island in 
S. pneumoniae [100, 104], and in novel genomic islands in S. agalactiae [99, 105]. 
3.4 Exportal 
A distinct microdomain termed the ExPortal has been identified in S. pyogenes which 
contains a high concentration of the Sec translocon component SecA [106].  Immunogold 
electron microscopic analyses demonstrate the location of the ExPortal to a hemispherical 
position distal to either cell pole [106]. S. pyogenes secretes the cysteine protease SpeB 
exclusively through the ExPortal and its maturation protein HtrA co-localize with SecA 
at this domain (Figure 1) [106, 107]. However, in a recent study using SecA antiserum, it 
has been demonstrated that SecA was distributed throughout the periphery of the surface 
of S. pyogenes and was not confined to the single ExPortal as described in earlier studies 
[108].  Such differences may relate to the different M types used in each study.  
4 Protein retention 
Retention of streptococcal secreted proteins to the cell surface can be achieved by one of 
the following mechanisms: 1) covalent attachment to the cell wall by sortase enzymes; 2) 
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non-covalent association with other surface molecules such as teichoic acids and 
lipoteichoic acids; and 3) direct anchorage to the cytoplasmic membrane as lipoproteins. 
4.1  Covalently bound cell wall proteins 
Sortase (SrtA) is a membrane-associated transpeptidase that recognizes the C-terminal 
sortase recognition motif LPXTG [109]. SrtA homologs are responsible for anchoring the 
majority of LPXTG containing streptococcal surface proteins and have been identified in 
the genomes of S. pyogenes [110], S. gordonii [111], S. mutans [112], S. suis [94], S. 
pneumoniae [113], S. agalactiae [114], and S. sanguinis [115].  More than one sortase 
gene has been indentified in S. pyogenes [110], S. pneumoniae [116] and S. suis [117]. A 
class C sortase (SrtC2) has been recently identified in S. pyogenes which anchors a 
protein (Orf100) containing a QVPTGV motif to the cell surface [118].  
4.2  Non-covalently bound cell wall proteins 
The choline-binding proteins (CBPs) of S. pneumoniae and other Gram-positive bacteria 
all contain structurally similar choline-binding domains, which are composed of multiple 
copies of a repeat segment of around 20 amino acid residues referred to as the choline-
binding domain [119]. The choline-binding motif has also been identified in other 
exported proteins, including the glucan-binding protein of S. mutans [120] and 
glycosyltransferases of S. mutans and S. downei [121, 122].  
4.3  Lipoproteins 
Lipoproteins contain a distinctive lipoprotein signal motif LXXC in the N-terminus 
region which is subsequently cleaved by the type II signal peptidase and covalently 
attached to the palmitic acid in the cell membrane [123]. Several members of this family 
of proteins have been identified in S. pneumoniae including PpmA, SlrA, PsaA, PiaA, 
 19
and PiuA [123, 124]. Further, putative surface-associated lipoproteins have also been 
identified by surface proteome studies in S. pyogenes [39, 40, 59].  
4.4 Anchorless proteins 
Proteomic analyses of the streptococcal surface have revealed a number of anchorless 
proteins that do not possess the classical features such as signal sequences or membrane- 
anchor domains [39, 40, 43, 59]. Remarkably, the analysis has identified a significant 
number of traditional cytoplasmic proteins commonly thought to be intracellular in 
streptococci. Many of these proteins have been identified as virulence factors in 
streptococci, such as  the glycolytic pathway enzymes enolase and GAPDH, which have 
been identified as plasminogen-binding and cell wall-associated in S. pyogenes [125-127] 
and in S. pneumoniae [128].  
The mechanism of translocation and retention of these proteins is not yet known. 
It could be hypothesized that these proteins are either passively released during autolysis, 
or that an alternative secretory pathway may exist for these proteins. Recently it has been 
demonstrated that α-enolase of S. pneumoniae, which is one of the key enzymes in the 
glycolytic cycle, re-associates to the cell surface by interacting with receptors on 
encapsulated and unencapsulated pnuemococci [129]. This type of re-association 
mechanism may be utilized by the numerous anchorless proteins of streptococci, but 
further investigation is required. The enolase and GAPDH of Lactobacillus crispatus 
bind to the lipoteichoic acids on the bacterial surface in a pH-dependent manner, 
demonstrating for the first time a mechanism of glycolytic enzyme binding to the 
bacterial cell wall [130]. 
5 The development of vaccines against streptococcal infection 
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Traditionally, vaccines designed to prevent bacterial infection have been based on 
strategies including: 1) whole-cell vaccines containing heat-killed pathogens; 2) live 
attenuated vaccines constructed via inactivation of bacterial genes responsible for 
essential metabolic functions or pathogenicity; 3) toxoid-based preparations; 4) 
polysaccharides conjugated to suitable carrier proteins; and 5) subunit vaccines 
containing either a) whole proteins (purified or recombinant), b) minimal peptide 
epitopes, or c) cell wall and capsule antigens identified using biochemical, serological, 
microbiological, or genetic techniques. Such approaches were time-consuming, often 
taking many years or decades, and often failed when pathogens were difficult to 
culture in vitro [131]. However, a new era of vaccine development technology has 
emerged, aided by whole genome sequencing, bioinformatics, proteomics, and DNA 
microarrays. Such technologies have allowed rapid discovery and identification of 
putative virulence factors, surface-associated proteins and vaccine candidates. 
The development of human streptococcal vaccines is challenging, facing 
obstacles such as the occurrence of many unique serotypes, antigenic variation within 
the same serotype, differences in geographical distribution of serotypes, and the 
production of antibodies cross-reactive with human tissue which can lead to host auto-
immune disease. Streptococcal disease is a continuing worldwide problem, occurring 
in both developed and developing regions; thus the imperative for efficacious vaccines 
to prevent streptococcal disease is high. Furthermore, whilst antibiotics continue to be 
used to control streptococcal infection, there is increasing concern that such use, and 
particularly over-use, leads to the emergence of resistant strains [58, 132, 133]. 
Additionally, streptococci may avoid the effect of antibiotics via intracellular invasion 
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[134]. Although there are many candidate antigens and vaccine preparations under 
investigation, currently, for all streptococcal species, there are only two licensed 
human vaccines for use against pneumococcal infection. 
5.1 Pnuemococcal vaccines 
Although the two licensed S. pneumoniae vaccine preparations, comprising a 
conjugate heptavalent and a 23-valent vaccine, have been successful in reducing the 
incidence of streptococcal pneumonia and invasive pneumococcal disease caused by 
serotypes incorporated in the vaccine preparation [135-139], these have no protective 
effects against heterologous serotypes. Additionally, the 23-valent vaccine elicits a T-
cell independent immune response and is thus not suitable for use in children under 2 
years old or immunocompromised individuals. Comprehensive reviews of the different 
conjugate pneumococcal vaccine formulations and human clinical trials have been 
published by Wuoiimaa & Kayhty [140] and Oosterhuis-Kafeja et al. [135]. 
Pneumococci are genetically very flexible and can undergo natural transformation in 
order to obtain new phenotypic traits. Recombination events at operon(s) encoding 
capsule components can result in serotype switching, conferring the ability to evade 
the host immune system [141-143]. Consequently, high levels of diversity and 
evidence of capsule switching is observed in invasive pneumococcal isolates [144]. 
Given that the current capsule-based vaccines, both those licensed and those in pre-
clinical and clinical development only protect against included serotypes, and that the 
administration of such vaccines can result in serotype switching, it is thought that 
protein-based vaccines may result in broader protection against S. pneumoniae 
infection [145]. 
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Licensed pneumococcal vaccines and current vaccine candidates under 
investigation are outlined in Table 2. Whilst several protein-based vaccine 
preparations have been observed to protect in pre-clinical animal studies, and show 
promise as vaccine formulations, very few have reached human clinical trials. In other 
attempts to circumvent current problems associated with capsule polysaccharide 
(CPS)-based vaccines, several groups have used proteomic and bioinformatic based 
reverse engineering approaches to identify potential protein vaccine candidates. One 
proteomic study identified two immunogenic proteins, FBA and GAPDH, which were 
observed to protect against heterologous mucosal murine challenge [44]. A 
bioinformatics based study utilized an in silico whole genome screening approach to 
identify six vaccine antigens observed to protect against systemic challenge [146]. 
Such techniques show promise for the identification of efficacous vaccine candidates. 
5.2 Group A streptococcal vaccine development 
Currently there is no licensed vaccine to prevent group A streptococcal infection. 
Many surface-associated proteins have been identified and are under investigation as 
vaccine candidates (Table 3). GAS vaccinology has primarily focussed on the major 
virulence factor, the M protein. However, several factors have hampered the 
development of M protein-based vaccines such as the large number of unique M 
serotypes, the potential antigenic variation within a serotype due to the continual 
evolution of M protein [147], and the presence of cross-reacting epitopes which may 
trigger post-infective immune sequelae [148]. Futhermore, circulating GAS strains can 
rapidly be replaced by a new set of strains [149, 150]. As a consequence, N-terminal 
multivalent M protein vaccine preparations may need to be continuously reformulated 
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in order to protect against current circulating strains. On the other hand, non-M protein 
GAS vaccine candidates are generally highly conserved and have not been observed to 
result in the generation of cross-reactive antibodies. Several non-M protein vaccine 
candidates have been extensively investigated and shown to be protective in pre-
clinical animal studies (Table 3), although, to our knowledge, none of these have 
reached human clinical trials. 
M proteins are an obvious target for vaccine development as they are known to 
be a major virulence factor in GAS and have elicited protective immunity in several 
studies. Early studies involving vaccination of humans with crude M protein 
preparations followed by administration of live GAS to the pharynx effectively 
protected against GAS pharyngeal colonization [151-153], but one study noted an 
increased incidence of rheumatic fever in vaccinated versus unvaccinated control 
children [154]. This significantly hampered the development of whole M protein-
based vaccines. Since then, a number of vaccine development studies have targeted the 
C-terminal repeat region peptides, conserved amongst all serotypes [155, 156]; whilst 
other studies have focussed on polypeptides derived from the serotype specific N-
terminal repeats [157-162]. One group has developed a hexavalent vaccine containing 
protective N-terminal M protein fragments from six serotypes. The included serotypes 
were selected due to a frequent association with pharyngitis and acute rheumatic fever 
[162, 163]. This hybrid vaccine has been observed to generate high titre opsonising 
antibodies in rabbits [162] and to protect against murine mucosal challenge [164]. 
Recently, the vaccine was tested in phase I clinical trials and was found to produce a 
statistically significant increase in antibody titre for all six M protein fragments, with 
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five of the six serotypes being opsonised by the resulting anti-sera [163]. Additionally, 
there was no evidence the antibodies were cross-reactive with human tissue [163]. 
Although this vaccine was successful in phase I clinical trials, the major shortcoming 
of this hexavalent vaccine is that it only offers protection against six of an estimated 
120 GAS M-types. In an attempt to broaden the protection, a multivalent vaccine 
containing variable amino terminal fragments of 26 different M proteins was produced 
using recombinant techniques [165]. Following immunisation of rabbits, type-specific 
antibodies raised against 25 of the 26 M protein fragments in the vaccine were 
detected and none of these antibodies cross-reacted with host tissue [165]. 
Additionally, this vaccine preparation was observed to be safe and immunogenic in 
phase I clinical trials [166]. Although this vaccine preparation shows promise for the 
prevention of GAS infection, it is likely a vaccine protective against all serotypes will 
be necessary for the eradication of GAS infection and disease.  
In recent times, several proteomic studies of GAS have been carried out with 
the aim of identifying putative vaccine candidates. One such proteomic study, based 
on 2-DE and MALDI-TOF MS, identified 66 novel cell wall-associated proteins in 
three different strains of GAS [59]. Thirty-three proteins were observed to be 
immunoreactive with human antisera and 23 were suggested to be surface-exposed. 
Due to this surface localization and immunoreactivity data, such proteins may be 
suitable vaccine candidates. A proteomic trypsin digest of the cell-surface was utilised 
by Severin et al., in which a total of 79 surface-proteins were identified, 33 of which 
were novel surface-associated proteins in GAS [40]. These proteins are yet to be tested 
as vaccine candidates in pre-clinical animal studies. Rodríguez-Ortega et al. identified 
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14 surface-exposed proteins which were tested for protection in a murine disease 
model. One of these antigens, Spy0416, elicited protection following heterologous 
mucosal challenge [39]. Such proteomics-based screening approaches may result in 
the identification of vaccine candidates efficacious against GAS infection. 
5.3 Group B streptococcal vaccine development 
Like GAS, there is no commercial vaccine available to prevent S. agalactiae (GBS) 
infection. Whilst several vaccine candidates, both CPS and protein-based, are currently 
under investigation (Table 4), one of the biggest hurdles for GBS vaccinology is the 
legal liabilities of immunizing pregnant women in clinical trials, in which any adverse 
outcomes could be linked to the experimental vaccine [167]. Of the current vaccine 
candidates under development, conjugated CPS-based vaccines have been found to be 
protective and immunogenic for vaccine strains [168-175], but are costly due to 
individual conjugation of each CPS to the carrier protein. Protein-based vaccines are a 
potentially cheaper alternative and may offer broader protection against all nine 
circulating serotypes. 
Candidate GBS protein antigens have been identified using various proteomic 
and genomic screening methods. In a proteomic study of a GBS surface extract, 27 
proteins were identified [43]. Two of these proteins, OCT and PGK, were observed to 
confer a degree of protection in a neonatal murine infection model, and thus warrant 
further investigation as GBS vaccine candidates. More recently, the same research 
group used an alkaline phosphatase-based genetic screening method to identify outer 
surface proteins. Two of the identified proteins, Pho2-2 and Pho3-1 (a yutD 
homologue and an ABC transporter subunit, respectively), protected against 
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heterologous subcutaneous challenge in a rat neonatal disease model [60]. Multi-
genomic screening studies have also been utilized to identify potential GBS vaccine 
candidates. One group identified and tested a combination of four proteins, comprising 
surface immunogenic protein and three other putative surface-proteins, which were 
found to elicit protection in a neonatal murine disease model [50]. Furthermore, the 
combination of these proteins was found to protect against representative strains of all 
nine serotypes. 
5.4 S. mutans vaccine development 
Several surface antigens of S. mutans, the chief causative agents of dental caries, are 
also under investigation as vaccine candidates (Table 5). One of the limiting factors in 
the development of a vaccine to prevent dental caries is that it is a non-life-threatening 
disease and thus has a lower financial priority [176]. To date, limited proteomics 
studies have been performed on oral pathogens such as S. mutans and S. sobrinus, and 
those conducted primarily focus on growth under differing conditions rather than the 
identification of putative vaccine candidates. Refer to Macarthur & Jacques [177] for a 
review on the proteomic analysis of oral pathogens. 
5.5 Streptococcal vaccine development: future prospects 
Whilst there are many current vaccine candidates and newly emerging proteomics-based 
technologies leading to the identification of new candidates for S. pneumoniae, S. 
pyogenes and S. agalactiae, tested vaccine candidates for invasive zoonotic streptococcal 
strains such as S. suis or S. dysgalactiae subsp equisimilis and zooepidemicus are rare. 
Proteomic approaches may yield candidate vaccine antigens suitable for protection 
against human infection of these species. Although there are several streptococcal 
 27
vaccine preparations undergoing human clinical trials, the majority are designed 
predominantly to protect against strains in US and European populations. As the 
geographical distribution of strains is highly variable [178, 179], such preparations are 
often unsuitable for use in regions such as Asia, Africa and Oceania. If safe and 
protective universal vaccine candidates for streptococcal species can be trialed that elicit 
protection against all serotypes in humans, this would represent a major advance in 
human health. 
6 Conclusion 
The growing body of streptococcal proteomic data illustrates the usefulness of a 
proteomics-based approach in analyzing the cell surface topology of Gram-positive 
cocci, which lays the foundation for the future identification of novel virulence 
determinants, therapeutic agents and vaccine candidate antigens.  
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Figure legend 
Figure 1. Protein export pathways in Streptococcus. Ribosomally synthesized proteins 
can be sorted to various destinations. A) via the Sec pathway (proteins containing N-
terminal Sec-type signal peptide), B) via the TAT pathway (proteins containing twin 
arginine (RR/KR) signal peptides), C) via the pili-specific pathway, D) via the ExPortal, 
or E) via unknown export mechanisms (anchorless proteins). 
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None Group A 
 
S. pyogenes  
 
pharyngitis, pyoderma, erysipelas, 
bacteremia, septicemia,  
necrotising  fasciitis,  meningitis, 
pneumonia, septic arthritis, 
streptococcal toxic shock 
syndrome, scarlet fever, rheumatic 
feverb, glomerulonephritisb, 
reactive arthritisb, autoimmune 
neuropsychiatric disordersb 
HP [2, 3] 
None Group B 
 
S. agalactiae Invasive disease in neonates (<6 
days old): septicemia, pneumonia, 
meningitis, cellulites, 
osteomyelitis, septic arthritis 
Invasive disease in neonates (6 to 
90 days old): meningitis,  
bacteremia, necrotising fasciitis 
Perinatal disease:  mild urinary 
tract infection, puerperal sepsis, 
chorioamnionitis, endometirosis, 
cystitis, pyelonephritis, 




S. mitis Viridans S. pneumoniae otitis media, pneumonia,  
meningitis, septicemia, pleural 
empyema, septic arthritis, acute 
conjunctivitis 










(particularly S. anginosus), abscess 
(particularly S. constellatus), 
respiratory infections  (particulary 
S. intermedius)  including  












S. rattus  
S. sobrinus 






S. salivarius  
 
None S. salivarius,  
S. vestibularis 
bacteremia, endocarditis CO [189-
191] 
S. mitis or  




S. oralis  
throat infection, bacteremia, 




















Viridans S. constellatus 
subsp. pharyngis 
 












septicemia, septic arthritis, 
endocarditis, meningitis (S. 
zooepidemicus only), pneumonia 
(S. zooepidemicus only), toxic 





S. bovis  
 






S.  pasteuriana 
endocarditis, bacteremia, 
meningitis, septicemia 
S. bovis and S. infantarius are 
associated with severe 
inflammatory gastrointestinal 






Group G S. canis  
 
soft tissue infection, urinary tract 
infection, bacteremia, septicemia, 





Group E,  
P, U, V 
S. porcinus 
 
wound infection, urogenital tract 
infections in women, implicated  










meningitis, sepsis, toxic shock 































S. gallinaceus bacteremia 
 
ZO [23] 
Footnotes and abbreviations: a) the S. anginosus group was previously known as the S. milleri group; b) as sequelae; 
REFS, References; HP, common human pathogen; CO, commensal species causing opportunistic infection in humans;  
ZO, zoonotic streptococcal species causing opportunistic infection in humans. 
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Table 2 Licensed pneumococcal vaccines and vaccine candidates under investigation 
Antigen Function Comment Phase REFS 




T-cell-dependent response (immunological 







9-valent and  
11-valent 
Reduces incidence of disease. Safe and 
immunogenic. Only protects against limited 
serotypes. 
 





















Protects against systemic infection. Safe and 






adhesin A  
Metal 
binding  




protein C  
Adherence, 
colonization 
Protects against mucosal and systemic 
challenge. Not present in all strains. Highly 
variable. 
 





Intranasal immunization of mice reduced 
colonization following heterologous mucosal 
challenge. 
P [246] 





Iron uptake Protection against systemic homologous 
challenge. 




As stated Enhanced protection following mucosal and 
systemic challenge, multiple antigens may 
broaden protection. 
P [250, 251] 
Pneumolysin 
(PdB) 
Hemolysin Highly conserved sequence. Toxic for humans. 








Varying protection against heterologous 




Increased survival time and decreased 
colonization following mucosal challenge. 
P [261, 262] 
Autolysin Degrades 
cell wall 
Protection following systemic challenge. 
Limited protection following mucosal 
challenge. 
P [263, 264] 




Expression restricted to a subset of strains. 
Abbreviations: CPS, polysaccharide capsule; DT, diphtheria toxin; 6PGD, 6-Phosphogluconate 
dehydrogenase; PspA, Pneumococcal surface protein A; PsaA, Pneumococcal surface adhesin A; PdB, 
pneumolysin toxoid; P, Pre-clinical; I, Phase I clinical trial; II, Phase II clinical trial; III, Phase III clinical 
trial; L, Licensed REFS, references. 
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Table 3 Group A Streptococcal vaccine candidates under investigation 
Antigen Function Comment Phase REFS 
Group A Streptococcus (Streptococcus pyogenes) 
Protein-based 
Mucosal immunization reduces homologous 




Peptides protect against mucosal heterologous 






Whole   
M protein  
 
 
M protein  







phagocytic 6- and 26-valent immunogenic and safe in 










Reduced colonization following mucosal 




Protects against homologous systemic infection. 




Protection following systemic challenge. 






Protects against mucosal and systemic challenge. 






Mucosal immunization protects against 




Passive protection against systemic infection. 







Protection against systemic (not mucosal) 







Rabbits protected against challenge. Expression 
restricted to a subset of strains. 
P [285, 
286] 
SpeB Protease Mice protected against systemic heterologous 
challenge. 
P [287] 





Passive protection against systemic challenge.  P [289] 
Abbreviations: ARF, acute rheumatic fever; FbaA, Fibronectin-binding protein A; FBP54, Fibronectin-
binding protein 54; Spe, Streptococcal pyrogenic exotoxin; Sib35, Streptococcal Ig binding protein; Spa, 
Streptococcal protective antigen; P, Pre-clinical; I, Phase I clinical trial; II, Phase II clinical trial.  
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Table 4 Group B Streptococcal vaccine candidates under investigation 
Antigen Function Comment Phase REFS 
Group B Streptococcus (Streptococcus agalactiae) 
Based on Polysaccharide Capsule (CPS) 
Type III 
polysaccharide 
Safe and well tolerated but only 63% 





Vast improvement in immunogenicity. Only 









Protective in murine neonatal model. Well 
tolerated in humans, but preparing individual 
















Alternative carrier proteins include: C protein, 
C5a peptidase, diphtheria toxin, hepatitis B 






C protein  
(α and β)  
Surface-
associated 
Passive protection against systemic infection. 





Mice protected from heterologous challenge. 
Murine neonatal immunization model not 
explored. 
P [304] 
C5a peptidase Cleaves C5a 
(complement) 
Highly conserved. Immunization resulted in 
enhanced clearance following mucosal 
challenge. 




Active and passive protection against systemic 




repeat protein  
Surface-
associated  
Found in strains representing all nine 







Limited knowledge of proteins function. 
Protection against subcutaneous challenge in 




Found on all serotypes. Mice protected against 
heterologous systemic challenge. 
P [308, 309] 
R28 (Alp3) Surface-
associated 
Protection against systemic challenge 
following passive and active immunization. 
P [282, 310] 
Rib protein Surface-
associated  
Protection following mucosal challenge and 
systemic heterologous challenge. 
P [311-313]  
Abbreviations: CPS, Polysaccharide capsule; TT, Tetanus toxoid; BPS, Group B protective surface 
protein; Sip, Surface immunogenic protein; Rib, Resistance to proteases, immunity, group B; P, Pre-
clinical; I, Phase I clinical trial. 
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Table 5 Streptococcus mutans vaccine candidates under investigation 
Antigen Function Comment Phase REFS 
Streptococcus mutans 
Antigen I/II  Surface 
adhesin 
Active and passive immunization of animals and 








Reduced colonization following active and 
passive immunization. Immunogenic, well 









Active and passive immunization reduced dental 






Antigen I/II  
As above Significant reduction in colonization following 





Abbreviations: GTF, Glucosyltransferase; P, Pre-clinical; I, Phase I clinical trial. 
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